Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
KV1.3 Channel Inhibitor
ShK toxin is a potent inhibitor of the voltage-dependent potassium channel (Kv1.3), derived from the Caribbean sea anemone Stichodactylus helianthus. This toxin competitively interacts with dendrotoxin I and α-dendrotoxin at synaptosomal membranes, enhancing acetylcholine release. In addition to its neural effects, ShK toxin effectively suppresses K+ currents in cultured rat dorsal root ganglion neurons and demonstrates significant inhibition of T lymphocyte proliferation. It serves as a valuable tool in studies of neurophysiology and immunology. -
Kir2 Inhibitor
ML-133 is a selective inhibitor of the Kir2 family of potassium channels, exhibiting an IC50 of 1.8 μM at pH 7.4 and 290 nM at pH 8.5. This compound serves as a valuable tool for investigating the role of Kir2 channels in various physiological processes and pathophysiological conditions. Its ability to modulate potassium ion flow makes it applicable in studies related to cardiac function, neuronal signaling, and other cellular activities influenced by Kir2 channel activity. -
Kv 1.5 Inhibitor
BMS-394136 is a selective inhibitor of the Kv 1.5 potassium channel, exhibiting an IC50 of 0.05 μM. This compound effectively prolongs the atrial effective refractory period (AERP) and action potential duration (APD) in a dose-dependent manner while leaving the ventricular effective refractory period (VERP) unaffected. BMS-394136 is particularly useful for research focused on acute atrial ischemia and related cardiac electrophysiological studies. -
Ion Channel Inhibitor
Nerispirdine is an ion channel inhibitor that selectively targets voltage-gated potassium channels K(v)1.1 and K(v)1.2, exhibiting IC50 values of 3.6 µM and 3.7 µM, respectively, and also inhibits voltage-dependent sodium channels with an IC50 of 11.9 µM. As a derivative of 4-aminopyridine, Nerispirdine serves as a valuable tool in the investigation of neurological disorders, contributing to research focused on channelopathies and synaptic transmission. Its potential for modulating ion channel activity makes it a significant compound for studying electrophysiological processes. -
Kv1.5 Channel Inhibitor
MSD-D is a potent Kv1.5 channel inhibitor, exhibiting a frequency-dependent mechanism with an IC50 value of 0.5 μM. This compound is promising for research into atrial-selective class III antiarrhythmics, offering potential insights into cardiac arrhythmias and related therapies. -
hERG Inhibitor
6-O-Desmethyl donepezil is a potent hERG channel inhibitor, exhibiting an IC50 value of 1 μM. As a metabolite of Donepezil, it is instrumental in studying cardiac ion channel activity and the potential implications of drug interactions. This compound is valuable for research in cardiotoxicity and pharmacology, particularly in the context of drug development and assessment of cardiac safety profiles. -
bTREK-1 Potassium Channel Inhibitor
6-Bnz-cAMP (N6-Benzoyl-cAMP) is a potent inhibitor of the bTREK-1 potassium channel, functioning through a protein kinase A (PKA) independent mechanism. This compound is instrumental in investigating the roles of signal transduction proteins within the cAMP signaling pathway. Its use can aid in elucidating the physiological and pathophysiological processes mediated by bTREK-1 and cAMP-related signaling cascades. -
Potassium Channel Inhibitor
(BrMT)2 is a non-peptide potassium channel inhibitor that primarily targets Kv1.1 channels. It effectively slows the activation kinetics of these channels, making it a valuable tool for elucidating the physiological roles of potassium channels in various cellular processes. This compound is useful in research applications focusing on neurophysiology, cardiac function, and other studies involving ion channel modulation. -
Potassium Channel Inhibitor
CS476 is a potent inhibitor of potassium channels, exhibiting significant hypoglycemic activity. This compound may facilitate research into the modulation of glucose homeostasis and has potential applications in the study of diabetes-related pathways. Its ability to influence potassium channel activity makes it a valuable tool for investigating various cellular processes linked to metabolic regulation. -
Proton Pump Inhibitor
Zastaprazan citrate is a proton pump inhibitor that functions as a potent potassium-competitive acid blocker. This compound is primarily utilized in research related to gastrointestinal inflammatory disorders and gastric acid-related conditions, including gastroesophageal reflux disease. Its ability to effectively inhibit gastric acid secretion makes it a valuable tool for studying underlying mechanisms of these diseases. -
Proton Pump Inhibitor
Azeloprazole sodium is a potent proton pump inhibitor (PPI) that effectively reduces gastric acid secretion. This compound is primarily used in research related to gastroesophageal reflux disease (GERD), facilitating studies on acid-related gastrointestinal disorders and therapeutic interventions. Its mechanism of action provides valuable insights into the regulation of gastric proton pumps and their role in acid-mediated conditions. -
PM Ca2+-ATPase Inhibitor
Caloxin 2A1 is a selective inhibitor of the plasma membrane Ca2+-ATPase (PMCA), functioning at the extracellular level. This peptide demonstrates a targeted inhibition of PMCA activity without influencing basal Mg2+-ATPase or Na+-K+-ATPase activity. It serves as a valuable tool in studies investigating calcium homeostasis and its implications in cellular signaling and physiology. -
Proton Pump/Potassium-competitive Acid Inhibitor
Abeprazan hydrochloride is a potassium-competitive acid inhibitor that selectively targets H+, K+-ATPase, providing a mechanism of action distinct from traditional proton pump inhibitors. By reversibly binding in a potassium-competitive manner, Abeprazan hydrochloride effectively reduces gastric acid secretion without requiring acid activation. This compound is being investigated for its therapeutic potential in treating various acid-related gastrointestinal disorders. -
Proton Pump/Potassium-competitive Acid Inhibitor
Abeprazan is a potassium-competitive acid inhibitor primarily targeting the H+, K+-ATPase enzyme. By reversibly binding to this enzyme through potassium-competitive ionic interactions, it effectively reduces gastric acid secretion without the need for acid activation. Abeprazan is being developed as a potential alternative to traditional proton pump inhibitors for the management of acid-related disorders, providing a novel approach to acid control in clinical applications. -
v-ATPase Inhibitor
Verucopeptin is a selective v-ATPase inhibitor that targets the ATP6V1G subunit, effectively reducing v-ATPase activity. This compound has a notable impact on HIF-1 signaling, decreasing the expression of HIF-1α and its target genes. Additionally, Verucopeptin demonstrates antitumor properties against multidrug resistant (MDR) cancers, making it a valuable tool for cancer research. Its specific mechanism and biological activity position it as a significant reagent for studies focused on tumor biology and therapy resistance. -
H+/K+-ATPase Inhibitor
(R)-Tegoprazan is a potent H+/K+-ATPase inhibitor characterized by its benzimidazole structure. It demonstrates an IC50 of 98 nM against canine kidney Na+/K+-ATPase, highlighting its efficacy in modulating ion transport. This compound is prominently applied in research related to gastrointestinal diseases, offering valuable insights into therapeutic interventions. -
Proton Pump Inhibitor
Zastaprazan is a potent proton pump inhibitor that functions as a potassium-competitive acid blocker. It is utilized in research related to gastrointestinal inflammatory diseases and gastric acid-related conditions, including gastroesophageal reflux disease. This compound provides valuable insights into mechanisms of acid secretion and potential therapeutic approaches in the treatment of acid-related disorders. -
Proton-pump Inhibitor
5-Hydroxylansoprazole is a metabolite of Lansoprazole, acting as a proton-pump inhibitor. This compound is instrumental in reducing gastric acid secretion, thereby aiding in the treatment of various peptic disorders. Its primary application in research includes the investigation of acid-related gastrointestinal conditions and the pharmacokinetics of proton-pump inhibitors. -
Proton Pump Inhibitor
Padoprazanum is a proton pump inhibitor that works by irreversibly blocking the H+/K+ ATPase enzyme in the gastric parietal cells. This inhibition effectively reduces gastric acid secretion, making it useful in the treatment of various acid-related gastrointestinal disorders. Key research applications include the investigation of acid secretion mechanisms and the study of therapeutic strategies for conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. -
PM H+-ATPase Inhibitor
Protonstatin-1 is a selective inhibitor of the plasma membrane H+-ATPase, exhibiting an IC50 of 3.9 μM. By interacting with the central loop of the enzyme, Protonstatin-1 disrupts the functions of the N- and P-domains, ultimately inhibiting pump activity and auxin transport. This reagent is valuable for research in plant physiology and studies involving cellular ion homeostasis. -
V-ATPase Inhibitor
V-ATPase-IN-1 is a selective inhibitor of Vacuolar-type H+-ATPases (V-ATPase), demonstrating an IC50 value of 194.80 μM and a binding affinity for the V-ATPase subunit A with a Kd of 0.803 μM. This compound exhibits notable insecticidal activity against M. separata, with an LC50 of 2.64 mM. V-ATPase-IN-1 is a valuable tool in research focused on the development of chemical insecticides and understanding the biological role of V-ATPase in various organisms. -
H+-K+-ATPase Inhibitor
(±)-Vasicine is a potent inhibitor of H+-K+-ATPase, with an observed IC50 of 73.47 μg/mL. This compound exhibits notable anti-ulcer properties, demonstrating significant anti-secretory, antioxidant, and cytoprotective effects. As such, (±)-Vasicine serves as a valuable reagent for research applications focused on gastrointestinal protection and related mechanisms in cellular physiology. -
H(+), K(+)-ATPase Inhibitor
Lansoprazole sulfone is a selective inhibitor of H+, K+-ATPase, primarily targeting gastric acid secretion. By inhibiting this enzyme, lansoprazole sulfone may significantly stimulate gastric acid secretion, making it a valuable tool in research related to gastric physiology. Its potential applications extend to the study of conditions such as duodenal ulcers, gastric ulcers, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. -
RUVBL1/2 ATPase Inhibitor
TIP48/49-IN-1 is a selective inhibitor of the RUVBL1/2 ATPase, demonstrating an IC50 of 59 nM against purified RUVBL1/2. By disrupting the DNA replication process, TIP48/49-IN-1 induces S-phase arrest and apoptosis in cancer cells. This compound has been shown to inhibit tumor growth and enhance radiosensitivity in non-small cell lung cancer (NSCLC) models, making it a valuable tool for cancer research. -
Proton Pump Inhibitor
Padoprazanum hydrochloride is a proton pump inhibitor that selectively targets gastric proton pumps, reducing acid secretion in the stomach. This compound demonstrates significant efficacy in the treatment of acid-related disorders such as gastroesophageal reflux disease (GERD) and peptic ulcers. Its unique mechanism of action makes it a valuable tool for researchers studying gastric secretion and related gastrointestinal conditions. -
Proton Pump Inhibitor
Omeprazole magnesium is an orally active proton pump inhibitor (PPI) that effectively suppresses gastric acid secretion. It is utilized in research related to acid reflux symptoms and frequent heartburn, making it a valuable tool for investigating gastrointestinal disorders and related therapeutic interventions. -
Proton Pump Inhibitor
Linaprazan mesylate is a proton pump inhibitor that targets the H+,K+ -ATPase enzyme in the gastric mucosa through competitive binding with potassium ions. With an IC50 value of 1.0 ± 0.2 μM, it exhibits potent inhibitory effects on gastric acid secretion. This compound is particularly applicable in studies related to gastroesophageal reflux disease and reflux esophagitis, facilitating research on its therapeutic potential. -
H+, K+-ATPase Inhibitor
S 1924 is a potent H+, K+-ATPase inhibitor, demonstrating IC50 values of 10.3 μM at pH 7.4 and 1.6 μM at pH 6.0. This compound effectively modulates gastric acid secretion, making it valuable in research related to gastrointestinal physiology and pharmacology. Its specificity for H+, K+-ATPase makes S 1924 a useful tool for investigating proton pump mechanisms and related therapeutic targets. -
Proton Pump Inhibitor
AGN-201904Z is a novel proton pump inhibitor that effectively inhibits gastric acid secretion. This compound demonstrates enhanced and sustained acid suppression effects compared to traditional agents such as esomeprazole. AGN-201904Z is valuable for research applications aimed at studying gastric disorders and evaluating the physiological impacts of prolonged acid suppression. -
Proton Pump Inhibitor
Saviprazole is a proton pump inhibitor that effectively reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells. This compound demonstrates significant biological activity in the treatment of gastrointestinal diseases, particularly in conditions such as gastric ulcers and acid reflux. Its application in research provides valuable insights into acid-related disorders and potential therapeutic interventions. -
Proton Pump Inhibitor
Tiludronate, a bisphosphonate with proton pump inhibitor activity, primarily targets the osteoclast vacuolar H(+)-ATPase to regulate bone metabolism. It exhibits potent antiresorptive and anti-inflammatory properties, making it valuable for studying metabolic bone disorders. Its role in inhibiting osteoclast function positions Tiludronate as a critical tool for research focused on bone health and related diseases. -
Proton Pump Inhibitor
Padoprazanum fumarate is a proton pump inhibitor that targets the H+/K+ ATPase enzyme in gastric parietal cells, effectively reducing gastric acid secretion. It demonstrates notable efficacy in the treatment of conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. This compound serves as a valuable tool for researchers investigating gastric acid regulation and related gastrointestinal disorders. -
V ATPase Inhibitor
FR-167356 is a selective inhibitor of vacuolar ATPase, exhibiting potent activity with IC50 values of 170 nM for osteoclast plasma membranes, 220 nM for macrophage microsomes, and higher values for renal brush border and liver lysosomal membranes. This compound inhibits bone resorption and effectively addresses ovariectomy-induced bone loss. It serves as a valuable tool for research into osteoporosis and related bone disorders. -
Proton Pump Inhibitor
WY-47766 is a potent proton pump inhibitor that targets the gastric H+/K+ ATPase enzyme. Its primary mechanism involves the irreversible binding to the enzyme, leading to a significant reduction in gastric acid secretion. WY-47766 is utilized in research applications focused on understanding gastric physiology, acid secretion disorders, and the development of therapeutic strategies for related gastrointestinal diseases. -
Proton Pump Inhibitor
(R)-(+)-Pantoprazole sodium is a potent proton pump inhibitor that selectively targets the H+/K+ ATPase enzyme in gastric parietal cells. This compound is primarily utilized in research related to gastroesophageal reflux disease, aiding in the elucidation of gastric acid secretion mechanisms and therapies. Its ability to effectively reduce gastric acidity makes it a valuable tool for studying acid-related disorders and developing therapeutic strategies. -
V-ATPase Inhibitor
Apicularen B is a potent V-ATPase inhibitor derived from the myxobacterium Archangium gephyra. This cytotoxic macrolide exhibits significant biological activity relevant to the study of V-ATPase-related disorders, including osteopetrosis. Researchers can utilize Apicularen B to investigate the mechanisms underlying these diseases and explore potential therapeutic applications. -
proton pump Inhibitor
AGN-201904 is a proton pump inhibitor that functions as an omeprazole prodrug. This compound has shown potential in delaying aging processes and is effective in the prevention and inhibition of peptic ulcers. Its biological activity makes it a valuable tool in research focused on gastrointestinal health and the mechanisms of aging. -
H+/K+-ATPase Inhibitor
KR-60436 is a reversible inhibitor of H+/K+-ATPase, effectively obstructing proton and potassium transport across cellular membranes. This compound has demonstrated potent inhibition of CYP1A2 substrate metabolism, making it a valuable tool for studying gastric proton pump activity and its implications in drug metabolism. Its utility extends to drug interaction studies and the investigation of gastrointestinal pharmacology. -
Proton Pump Inhibitor
SKF96067 is a reversible inhibitor of the gastric H+/K+-ATPase, primarily targeting proton pumps involved in gastric acid secretion. This compound demonstrates significant biological activity in reducing gastric acid production, making it useful in research related to gastrointestinal diseases and acid-related disorders. Its modulation of proton pump activity aids in elucidating mechanisms of acid secretion regulation and the potential therapeutic effects on related pathologies. -
Proton Pump Inhibitor
Nepaprazole is a proton pump inhibitor that targets H+/K+-ATPase activity, significantly reducing gastric acid secretion. It demonstrates inhibitory effects in isolated rabbit gastric mucosal microsomes with IC50 values of 5.8 μM and 9.9 μM at pH 6.0 and pH 7.4, respectively. This compound is primarily utilized in research related to peptic ulcer diseases, providing insights into gastric acid regulation and potential therapeutic interventions. -
Proton Pump Inhibitor
Tenatoprazole sodium is a potent proton pump inhibitor that specifically targets the hog gastric H+/K+-ATPase, exhibiting an IC50 of 6.2 μM. This compound effectively decreases gastric acid secretion, making it valuable for research in gastrointestinal disorders and related therapeutic applications. Its mechanism of action positions it as a useful tool for studying the regulation of gastric acidity and the underlying pathways involved in acid-related diseases. -
Proton Pump Inhibitor
S3337 is a potent inhibitor of H+, K+-ATPase, a key enzyme responsible for regulating gastric acid secretion. By targeting this proton pump, S3337 effectively reduces gastric acid production, making it valuable for research into acid-related disorders. Its primary applications include studies on gastritis, peptic ulcers, and gastroesophageal reflux disease (GERD). -
SGLT2 Inhibitor
WAY-123783 is a selective and orally active sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor. It effectively enhances urinary glucose excretion while simultaneously lowering blood glucose levels in db/db mice, with an ED50 of 9.85 mg/kg. This compound is valuable for research in metabolic diseases, particularly diabetes, facilitating studies on glucose regulation and potential therapeutic interventions. -
SGLT2 Inhibitor
SGLT2-IN-1 is a selective inhibitor of the sodium-dependent glucose cotransporter SGLT2, exhibiting an IC50 of 33 nM in CHO cells transfected with human SGLT2. This compound demonstrates selectivity for SGLT2 over SGLT1, making it a valuable tool for research in glucose homeostasis and metabolic disorders. Additionally, SGLT2-IN-1 serves as an active metabolite of dapagliflozin, contributing to studies focused on diabetes and its associated complications. -
SGLT2 Inhibitor
Henagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 value of 2.38 nM for human SGLT2, exhibiting minimal activity against SGLT1 with an IC50 of 4324 nM. This compound is instrumental in diabetes research, facilitating studies on glucose homeostasis and potential therapeutic strategies for diabetic conditions. Its high selectivity and potency make it a valuable tool for investigating the physiological and pharmacological roles of SGLT2 in metabolic disorders. -
SGLT-2 Inhibitor
Enavogliflozin is a highly selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor that exhibits potent antidiabetic activity. By inhibiting SGLT-2, Enavogliflozin reduces glucose reabsorption in the kidneys, promoting increased glucose excretion in urine and thereby lowering blood glucose levels. This compound is primarily employed in research applications focused on diabetes management and cardiovascular health. -
SGLT-2 Inhibitor
Tianagliflozin is a selective inhibitor of sodium/glucose cotransporter 2 (SGLT-2), offering potential therapeutic benefit in the management of type 2 diabetes mellitus. By inhibiting SGLT-2, Tianagliflozin promotes the excretion of glucose through the kidneys, thereby lowering blood glucose levels. This compound is of interest in research focused on innovative treatments for glycemic control and metabolic regulation in diabetic patients. -
SGLT2 Inhibitor
Remogliflozin etabonate is a selective inhibitor of the sodium glucose cotransporter 2 (SGLT2), exhibiting Ki values of 1.95 μM for human SGLT2, 2.14 μM for rat SGLT2, 43.1 μM for human SGLT1, and 8.57 μM for rat SGLT1. As a prodrug derived from benzylpyrazole glucoside, it is metabolized into its active form, Remogliflozin, in vivo. This compound demonstrates significant antidiabetic activity in rodent models, making it a valuable tool for research into glucose regulation and diabetes therapies. -
SGLT2 Inhibitor
Sergliflozin etabonate is a potent and orally active sodium-glucose cotransporter 2 (SGLT2) inhibitor. It exhibits significant antidiabetic and antihyperglycemic effects, as evidenced by its ability to markedly reduce non-fasting blood glucose levels in diabetic mouse models. This compound is primarily utilized in diabetes research to explore therapeutic strategies for glucose management and metabolic regulation. -
SGLT1/SGLT2 Inhibitor
SGLT1/2-IN-1 is a dual inhibitor of SGLT1 and SGLT2, designed to effectively modulate glucose transport mechanisms. This compound exhibits significant biological activity in reducing glucose reabsorption in the kidneys and intestines, making it a valuable tool for research in diabetes and metabolic disorders. Its applications extend to investigating the role of sodium-glucose transporters in glucose homeostasis and potential therapeutic interventions for hyperglycemia.
